

19/61

[illegible]

Fig1 Tab 1A: signal/ noise ratio for the RNA selection for D-ghrelin binding aptamers

abbreviations:

NA - neutravidin agarose
UL - streptavidin ultralink

CR	-	collection round
DR	-	double round (selection round without amplification with RNA from CR)

Fig. 1

BEST AVAILABLE COPY

10/522582

2/61

	1. round	2. round	3. round	4. round	5. round	6. round	7. round	8. round	9. round	10. round	11. round	12. round	test for blocking 12. round	CR (1) 12. round	DR (1)	test for blocking	CR (2) 14. round	DR (2)	test for blocking	CR (3) 15. round	DR (3)
MARTIS	NA	NA	UL	UL	NA	NA	UL	UL	NA	NA	UL	UL		UL	UL	UL	UL	UL			
3rdM																					
1stM																					
5thM	73	473						217													
3rdM																					
15thM																					
16thM			8	4	22	134					43										
5thM						99	19					141				453	478				
21stM							9	21													
16thM								9	393												
2ndM								79													
11thM									28												
5thM									33	17	3	3						145			115
																		19			38,6

Fig 2 Tab1B: signal/ noise ratio for the 2'-P-RNA selection for D-ghrelin binding aptamers

abbreviations:

NA - neutravidin agarose

UL - streptavidin ultralink

CR - collection round

DR - double round (selection round without amplification with RNA from CR)

Fig. 2

BEST AVAILABLE COPY

3/61

	round 1	round 2-5	round 6-11/12	collection rounds
RNA	6nmol	1nmol	500pmol	1000pmol
2'F-RNA	3nmol	1nmol	500pmol	1000pmol

Fig 3: amount of RNA/ 2'F-RNA used in the selection process

Fig. 3

BEST AVAILABLE COPY





Fig.4A: course of the ghrelin peptide concentration for the RNA selection

5/61



FigAB: course of the ghrelin peptide concentration for the 2F-RNA selection

BEST AVAILABLE COPY

BEST AVAILABLE COPY

6/61




Fig. 5: Course of eluted RNA in percent of total used RNA and peptide concentration

BEST AVAILABLE COPY




Fig.6: course of eluted 2'-F-RNA in percent of total used 2'-F-RNA and peptide concentration

10/522383

8/61

	test for binding	CR (1)	DR (1)	test for binding	SCR (2)	DR (2)	test for binding	CR (3)	DR (3)
round	12	12	12	13	13	13	14	14	14
C									
[ghrelin]									
3µM		31,6							
1µM	22,6			32,5	14,5		53,8		
300nM	4,98			15,6			35,7	25,3	
100nM	0,78			7,9			28,2		
30nM	0,15			3,1			9,9		
10nM	0,13		1,05	1,55		6,33*	3,5		6,7*

Fig.7A Tab.3: double rounds and binding assays performed from round 12 to 14 for the RNA selection; data in percent binding to D-ghrelin, * sequenced

Fig. 7A

BEST AVAILABLE COPY

9/61

BEST AVAILABLE COPY




Fig.7B: Improvement of the RNA pool binding to D-ghrelin monitored over the double rounds

10/61

	test for binding	CR (1)	DR (1)	test for binding	CR(2)	DR (2)	test for binding	CR (3)	DR (3)
round	13	13	13	14	14	14	15	15	15
C									
[ghrelin]									
3µM	42,4	31,4							
1µM	28,8			45	28,7				
300nM	16,5			35,2			32,7	19,6	
100nM	8,49			29			26,5		
30nM	3,76			9,4			18,1		
10nM	0,72			3,9			9,1		
1nM			0,95				1,7		
500pM			0,43			5,82*			5,75
						0,75			1,93*

Fig.8A Tab4: double rounds and binding assays performed from round 13 to 15 for the 2 F-RNA selection; data in percent binding to D-ghrelin, * sequenced

Fig. 8A

BEST AVAILABLE COPY

10/522582

11/61




Fig.8B: Improvement of the 2F-RNA pool binding to D-ghrelin monitored over the double rounds

BEST AVAILABLE COPY

12/61

Automated *In vitro*-Selection against Rat D-Ghrelin

Round No.	A	B	C	Vold	Remarks
1	1 μ M				manual round
2	1 μ M				manual round
3	5 W	10 W	15 W	vold 5 W	wash volume: 90 μ l per wash (W) [D-Ghrelin] = 500 nM
4	5 W	10 W	15 W	vold 5 W	
5	500 nM	167 nM	56 nM	vold	15 washes from round 5
6	500 nM	167 nM	56 nM	vold	
7	500 nM	167 nM	56 nM	vold	
8	500 nM	167 nM	56 nM	vold	
9	167 nM	56 nM	19 nM	vold	
10	167 nM	56 nM	19 nM	vold	
11	167 nM	56 nM	19 nM	vold	
12	56 nM	19 nM	6.2 nM	vold	
13	56 nM	19 nM	6.2 nM	vold	
14	56 nM	19 nM	6.2 nM	vold	
15	56 nM	19 nM	6.2 nM	vold	
16	19 nM	6.2 nM	2.1 nM	vold	
17	19 nM	6.2 nM	2.1 nM	vold	
18	6.2 nM	2.1 nM	0.7 nM	vold	
19	6.2 nM	2.1 nM	0.7 nM	vold	

BEST AVAILABLE COPY

Fig. 9

131522169

13/61

Workspace of the Robot for Automated *in vitro*-Selection of RNA




Fig. 10

BEST AVAILABLE COPY




Fig. 11

10/522589

BEST AVAILABLE COPY

15/61

Table 5

Position in Fig. 13	Identifier	Total Occurrence	Occurrence Round 17	Occurrence Round 19
1	B11	65		
7	E3	5	35	30
13	F12	2		5
4	B7	2	1	1
5	A8	2		2
9	C11	2		2
10	A3	2		2
15	G5	1	2	
11	F5	1	1	
2	G2	1	1	
6	B12	1	1	
12	A12	1		1
3	E12	1		1
8	C12	1		1

Fig. 12

101529592

16/61

Sequences of the (+) strand

complete forms:

GGAGCUCAGACUUCACUCGUGUG---AGGCCAAU-----AAAACU---UAAGUCCGAAGGUAACCAUCCUAC--ACGUACCACUUGCGGUCCAC B11
GGAGCUCAGACUUCACUCGUGUG---AGGCCAGU-----AAAACU---UAAGUCCGAAGGUAACCAUCCUAC--ACGUACCACUUGCGGUCCAC G2
GGAGCUCAGACUUCACUCGUGUG---AGGCCAAU-----AAAACU---UAAGUCCGAAGGUAACCAUCCUAC--ACGUACCACUUGCGGUCCAC E12
GGAGCUCAGACUUCACUCGUGUG---AGGCCAAU-----AAAACA---UAAGUCCGAAGGUAACCAUCCUAC--ACGUACCACUUGCGGUCCAC B7
GGAGCUCAGACUUCACUCGUGUG---AGGCCAAU-----AAAACG---UAAGUCCGAAGGUAACCAUCCUAC--ACGUACCACUUGCGGUCCAC A8
GGAGCUCAGACUUCACUCGUGUG---AGGCCAAU-----AAAACU---UAAGUCCGAAGGUAACCAUCCUAC--ACGUACCACUUGCGGUCCAC B12
GGAGCUCAGACUUCACUCGUGUG---AGGCCAAU-----AAAACU---UAAGUCCGAAGGUAACCAUCCUAC--ACGUACCACUUGCGGUCCAC E3
GGAGCUCAGACUUCACUCGUGUG---AGGCCAAU-----AAAAC---GUAAGACCCGAAGGUAACCAUCCUAC--ACGUACCACUUGCGGUCCAC C12
GGAGCUCAGACUUCACUCGUGUG---AGGCCAAU-----AAAAC---GUAAGUCCGAAGGUAACCAUCCUAC--ACGUACCACUUGCGGUCCAC C11
GGAGCUCAGACUUCACUCGUGUG---AGGCCAAU-----AAAAC---GUAAGUCCGAAGGUAACCAUCCUAC--ACGUACCACUUGCGGUCCAC A3
GGAGCUCAGACUUCACUCGUGUG---AGGCCAAU-----AAAAC---GUAAGUCCGAAGGUAACCAUCCUAC--ACGUACCACUUGCGGUCCAC F5
GGAGCUCAGACUUCACUCGUGUG---AGGCCAAU-----AAAAC---GUAAGUCCGAAGGUAACCAUCCUAC--ACGUACCACUUGCGGUCCAC A12
GGAGCUCAGACUUCACUCGUGUG---AGGCCAAU-----AAAAC---GUAAGUCCGAAGGUAACCAUCCUAC--ACGUACCACUUGCGGUCCAC F12
GGAGCUCAGACUUCACUCGUGUG---AGGCCAAU-----AAAAC---GUAAGUCCGAAGGUAACCAUCCUAC--ACGUACCACUUGCGGUCCAC G5

GGAGCUCAGACUUCACUCG

DE.40P-Primer

CGUACCACUUGCGGUCCAC
DE.40R-Primer (rev. und
compl.)

Primer moieties underlined and in bold

Fig. 13-1

BEST AVAILABLE COPY

17/61

core forms:

B11	CGUGUAGGCCAUAUAAAUAUAAGUCCGAAGGUAACCAAUCCUAACG
G2	CGUGUAGGCCAGUAAAUAUAAGUCCGAAGGUAACCAAUCCUAACG
E12	CGUGUAGGCCAUAUAAAUAUAAGUCCGAAGGUAACCAAUCCUAACG
B7	CGUGUAGGCCAUAUAAAUAUAAGUCCGAAGGUAACCAAUCCUAACG
A8	CGUGUAGGCCAUAUAAAUAUAAGUCCGAAGGUAACCAAUCCUAACG
B12	CGUGUAGGCCAUAUAAAUAUAAGUCCGAAGGUAACCAAUCCUAACG
E3	CGUGCGUGAGGCHAAAACTUAAGUCCGAAGGUAACCAAUCCUAACG
C12	CGUGUAGGUAUAUAAAUAUAAGUCCGAAGGUAACCAAUCCUAACG
C11	CGUGUAGGUAUAUAAAUAUAAGUCCGAAGGUAACCAAUCCUAACG
A3	CGUGUAGGUAUAUAAAUAUAAGUCCGAAGGUAACCAAUCCUAACG
F5	CGUGUAGGUAUAUAAAUAUAAGUCCGAAGGUAACCAAUCCUAACG
A12	CGUGUAGGUAUAUAAAUAUAAGUCCGAAGGUAACCAAUCCUAACG
F12	CGUGUAGGUAUAUAAAUAUAAGUCCGAAGGUAACCAAUCCUAACG
G5	CGUGUAGGUAUAUAAAUAUAAGUCCGAAGGUAACCAAUCCUAACG

Fig. 13-2

SEE AVAILABLE COPY

10/522582

18/61




Fig. 14 A

BEST AVAILABLE COPY

10.022502




Fig. 14 B

BEST AVAILABLE COPY

10/522582




Fig. 14 C

BIO-AVAILABLE COPY

10/522582




Fig. 14 D

BEST AVAILABLE COPY

20050224

BEST AVAILABLE COPY




Fig. 14 E

Table 6

23/61

Clone B11

<u>[D-Ghrelin] in nM</u>	<u>% RNA bound</u>
0	0
3	2
10	8
30	35
100	62
300	76
1000	76
3000	83

Clone F12

<u>[D-Ghrelin] in nM</u>	<u>% RNA bound</u>
0	0
3	3
10	10
30	29
100	48
300	64
1000	91
3000	88

Clone E3

<u>[D-Ghrelin] in nM</u>	<u>% RNA bound</u>
0	0
3	1
10	5
30	20
100	54
300	65
1000	89
3000	85

Fig. 15

BEST AVAILABLE COPY

13/522582

24/61

Clone B11




Fig. 16 A

REST AVAILABLE COPY

10/5225

25/61

Clone F12




Fig. 16 B

BEST AVAILABLE COPY

10/522582

BEST AVAILABLE COPY

26/61

Clone E3




Fig. 16 C

10/522582

27/61

Table 7

Clone	K _D [nM]
A3	203
A8	98
A12	237
B7	139
B11	205
B12	135
C11	195
C12	17
E3	227
E12	171
F5	142
F12	111
G2	207
G5	164

Fig. 17

BEST AVAILABLE COPY

10/522582

28/61






Fig. 18

BEST AVAILABLE COPY

29/61

Clone B11

Clone B11trc



BEST AVAILABLE COPY

Fig. 19

10/5225

30/61

Table 8

Clone	K ₀ [nM]
D-B11	205
L-B11 trunc.	104
D-B11 trunc.	122

Fig. 20

BEST AVAILABLE COPY




Fig. 21

BEST AVAILABLE COPY

32/61

Sequences derived from the RNA selection (round 13)

RNA round 13

group1

1.1 main clone

'807-R04-DR13-B5

CGAGCTCAGACTTCTCTCTGTCGCTGACGACG-TAAGACCGAAGGTAAACATTCTTACCCAGTGAAGCGTGTCTGCTTCGAC

group2

2.1 main clone

'807-R04-DR13-A2

CGAGCTCAGACTTCTCTCTGTCGCTGACGACG-TAAGACCGAAGGTAAACATTCTTACCCAGTGAAGCGTGTCTGCTTCGAC

variations of 2.1

'807-R04-DR13-C4

CGAGCTCAGACTTCTCTCTGTCGCTGACGACG-TAAGACCGAAGGTAAACATTCTTACCCAGTGAAGCGTGTCTGCTTCGAC

group3

3.1 main clone

'807-R04-DR13-C1

CGAGCTCAGACTTCTCTCTGTCGCTGACGACG-TAAGACCGAAGGTAAACATTCTTACCCAGTGAAGCGTGTCTGCTTCGAC

group4

4.1 main clone

'807-R04-DR13-G2

CGAGCTCAGACTTCTCTCTGTCGCTGACGACG-TAAGACCGAAGGTAAACATTCTTACCCAGTGAAGCGTGTCTGCTTCGAC

Fig 22

BEST AVAILABLE COPY

Sequences derived from the RNA selection (round 14)

Fig. 23

BEST AVAILABLE COPY

34/61

Sequences derived from the 2'-P-RNA selection (round 14)
 2'-P-RNA round 14, group 1

1.1 (main clone)

'SOT-P03-DR14-G6 GGAAGTCAGAGCTTCACTCTGTGTGGAAATAGGAATTAAGTACTCAGAGCTTTCT-CATAGCTGCGCGCAGCAGAGTAAAGCACTGTGTGGTTCCAC
 mutations of clone 1.1
 1.2 'SOT-P03-DR14-P2 GGAAGTCAGAGCTTCACTCTGTGTGGAAATAGGAATTAAGTACTCAGAGCTTTCT-CATAGCTGCGCGCAGCAGAGTAAAGCACTGTGTGGTTCCAC
 1.3 'SOT-P03-DR14-P4 GGAAGTCAGAGCTTCACTCTGTGTGGAAATAGGAATTAAGTACTCAGAGCTTTCT-CATAGCTGCGCGCAGCAGAGTAAAGCACTGTGTGGTTCCAC
 1.4 GGAAGTCAGAGCTTCACTCTGTGTGGAAATAGGAATTAAGTACTCAGAGCTTTCT-CATAGCTGCGCGCAGCAGAGTAAAGCACTGTGTGGTTCCAC
 1.6 GGAAGTCAGAGCTTCACTCTGTGTGGAAATAGGAATTAAGTACTCAGAGCTTTCT-CATAGCTGCGCGCAGCAGAGTAAAGCACTGTGTGGTTCCAC
 1.7 'SOT-P03-DR14-G3 GGAAGTCAGAGCTTCACTCTGTGTGGAAATAGGAATTAAGTACTCAGAGCTTTCT-CATAGCTGCGCGCAGCAGAGTAAAGCACTGTGTGGTTCCAC
 1.8 GGAAGTCAGAGCTTCACTCTGTGTGGAAATAGGAATTAAGTACTCAGAGCTTTCT-CATAGCTGCGCGCAGCAGAGTAAAGCACTGTGTGGTTCCAC
 1.9 'SOT-P03-DR14-C2 GGAAGTCAGAGCTTCACTCTGTGTGGAAATAGGAATTAAGTACTCAGAGCTTTCT-CATAGCTGCGCGCAGCAGAGTAAAGCACTGTGTGGTTCCAC
 1.10 'SOT-P03-DR14-P3 GGAAGTCAGAGCTTCACTCTGTGTGGAAATAGGAATTAAGTACTCAGAGCTTTCT-CATAGCTGCGCGCAGCAGAGTAAAGCACTGTGTGGTTCCAC
 1.11 'SOT-P03-DR14-B6 GGAAGTCAGAGCTTCACTCTGTGTGGAAATAGGAATTAAGTACTCAGAGCTTTCT-CATAGCTGCGCGCAGCAGAGTAAAGCACTGTGTGGTTCCAC
 1.12 'SOT-P03-DR14-H1 GGAAGTCAGAGCTTCACTCTGTGTGGAAATAGGAATTAAGTACTCAGAGCTTTCT-CATAGCTGCGCGCAGCAGAGTAAAGCACTGTGTGGTTCCAC
 1.13 'SOT-P03-DR14-P6 GGAAGTCAGAGCTTCACTCTGTGTGGAAATAGGAATTAAGTACTCAGAGCTTTCT-CATAGCTGCGCGCAGCAGAGTAAAGCACTGTGTGGTTCCAC
 1.14 'SOT-P03-DR14-B1 GGAAGTCAGAGCTTCACTCTGTGTGGAAATAGGAATTAAGTACTCAGAGCTTTCT-CATAGCTGCGCGCAGCAGAGTAAAGCACTGTGTGGTTCCAC
 1.15 'SOT-P03-DR14-C1 GGAAGTCAGAGCTTCACTCTGTGTGGAAATAGGAATTAAGTACTCAGAGCTTTCT-CATAGCTGCGCGCAGCAGAGTAAAGCACTGTGTGGTTCCAC
 'SOT-P03-DR14-H5 GGAAGTCAGAGCTTCACTCTGTGTGGAAATAGGAATTAAGTACTCAGAGCTTTCT-CATAGCTGCGCGCAGCAGAGTAAAGCACTGTGTGGTTCCAC

Fig. 24 - 1

BEST AVAILABLE COPY

35/61

group22.1 (main clone)
'SOT-P03-DR14-05GGAGCTCAGAGCTTCTCTGTCGCGCTTCTGTTAGCTGCGGACCGTCACTGTCGCGGACCGAGATGCGTTACCGACTGTTCGTTCCAC**variations of clone 2.1**

2.2

'SOT-P03-DR14-D3

GGAGCTCAGAGCTTCTCTGTCGCGCTTCTGTTAGCTGCGGACCGTCACTGTCGCGGACCGAGATGCGTTACCGACTGTTCGTTCCAC

2.3

'SOT-P03-DR14-H2

GGAGCTCAGAGCTTCTCTGTCGCGCTTCTGTTAGCT-CCGACCGTCACTGTCGCGGACCGAGATGCGTTACCGACTGTTCGTTCCAC

2.4

'SOT-P03-DR14-D1

GGAGCTCAGAGCTTCTCTGTCGCGCTTCTGTTAGCT-CAGACCGTCACTGTCGCGGACCGAGATGCGTTACCGACTGTTCGTTCCAC

2.5

'SOT-P03-DR14-A2

GGAGCTCAGAGCTTCTCTGTCGCGCTTCTGTTAGCT-CAGACCGTCACTGTCGCGGACCGAGATGCGTTACCGACTGTTCGTTCCAC

2.6

'SOT-P03-DR14-Q2

GGAGCTCAGAGCTTCTCTGTCGCGCTTCTCT-...AGCTCTTACCGACCGTTCGCGGACCGAG-AGTTACCGACTGTTCGTTCCAC**group3**

3.1 main clone

'SOT-P03-DR14-H6

GGAGCTCAGAGCTTCTCTGTCGCGGCTTATGTCAGGCTTTCAGCGGACCGACTGCGGACCGAGATGCGTTACCGACTGTTCGTTCCAC

Fig. 24-2:

BEST AVAILABLE COPY

10/522582

36/61

Sequences derived from the 2^F-RNA selection (round 15)2^F-RNA round 15, group1

1.1 (main clone)
 'SOT-P03-DR15-010 GGAAGCTCAGAGCTTCTCACTCTGTTGGAAATAGGAAATGAACTGAGAGCTTTCT-CATAGGT-CCCCGACAGCAGTACGACTGTGCGTTCCAC
 1.2
 'SOT-P03-DR15-07 GGAAGCTCAGAGCTTCTCACTCTGTTGGAAATAGGAAATGAACTGAGAGCTTTCT-CATAGGT-CCCCGACAGCAGTACGACTGTGCGTTCCAC
 1.3
 'SOT-P03-DR15-F10 GGAAGCTCAGAGCTTCTCACTCTGTTGGAAATAGGAAATGAACTGAGAGCTTTCT-CATAGGT-CCCCGACAGCAGTACGACTGTGCGTTCCAC
 1.4
 'SOT-P03-DR15-D9 GGAAGCTCAGAGCTTCTCACTCTGTTGGAAATAGGAAATGAACTGAGAGCTTTCT-ATGT-CCCCGACAGCAGTACGACTGTGCGTTCCAC
 1.5
 'SOT-P03-DR15-F12 GGAAGCTCAGAGCTTCTCACTCTGTTGGAAATAGGAAATGAACTGAGAGCTTTCT-CATAGGT-CCCCGACAGCAGTACGACTGTGCGTTCCAC
 'SOT-P03-DR15-012 GGAAGCTCAGAGCTTCTCACTCTGTTGGAAATAGGAAATGAACTGAGAGCTTTCT-CATAGGT-CCCCGACAGCAGTACGACTGTGCGTTCCAC
 1.6
 'SOT-P03-DR15-H7 GGAAGCTCAGAGCTTCTCACTCTGTTGGAAATAGGAAATGAACTGAGAGCTTTCT-CATAGGT-CCCCGACAGCAGTACGACTGTGCGTTCCAC
 1.7
 'SOT-P03-DR15-A11 GGAAGCTCAGAGCTTCTCACTCTGTTGGAAATAGGAAATGAACTGAGAGCTTTCT-CATAGGT-CCCCGACAGCAGTACGACTGTGCGTTCCAC
 1.8
 'SOT-P03-DR15-A8 GGAAGCTCAGAGCTTCTCACTCTGTTGGAAATAGGAAATGAACTGAGAGCTTTCT-CATAGGT-CCCCGACAGCAGTACGACTGTGCGTTCCAC
 1.9
 'SOT-P03-DR15-P8 GGAAGCTCAGAGCTTCTCACTCTGTTGGAAATAGGAAATGAACTGAGAGCTTTCT-CATAGGT-CCCCGACAGCAGTACGACTGTGCGTTCCAC
 1.10
 'SOT-P03-DR15-C9 GGAAGCTCAGAGCTTCTCACTCTGTTGGAAATAGGAAATGAACTGAGAGCTTTCT-CATAGGT-CCCCGACAGCAGTACGACTGTGCGTTCCAC
 1.11
 'SOT-P03-DR15-C12 GGAAGCTCAGAGCTTCTCACTCTGTTGGAAATAGGAAATGAACTGAGAGCTTTCT-CATAGGT-CCCCGACAGCAGTACGACTGTGCGTTCCAC
 1.12
 'SOT-P03-DR15-P7 GGAAGCTCAGAGCTTCTCACTCTGTTGGAAATAGGAAATGAACTGAGAGCTTTCT-CATAGGT-CCCCGACAGCAGTACGACTGTGCGTTCCAC
 1.13
 'SOT-P03-DR15-A12 GGAAGCTCAGAGCTTCTCACTCTGTTGGAAATAGGAAATGAACTGAGAGCTTTCT-CATAGGT-CCCCGACAGCAGTACGACTGTGCGTTCCAC

group2

2.1
 'SOT-P03-DR15-C7 GGAAGCTCAGAGCTTCTCACTCTGTTGGAAATAGGAAATGAACTGAGAGCTTTCT-GAGTGGCCGACAGCAGTACGACTGTGCGTTCCAC

Fig. 25

BEST AVAILABLE COPY

37/61

GHSRC1_002 huGhrelin 031202





Fig. 26

10.13.25.95

38/61



BEST AVAILABLE COPY

39/61

GHSRC1_039 do/re B11V1 300403




Fig. 28

BEST AVAILABLE COPY


10/522582

REST AVAILABLE COPY

Fig. 29

40/61

GHSRC1_028 5 nM rat ghrelin 37°C



10/522582

BEST AVAILABLE COPY

41/61

GHSRC1_022 Vgl B11 - C12




Fig. 30

42/61

SEQ ID Identifier
NO

Sequence

101	SOT-108-H3	5'-X-GGTGGGTGAGGCACCCGTAAGTCCGAAGGTAAACCAATCCTACCCACC-Y-3'
102	SOT-108-A6	5'-X-GGTGGGTGAGGCATTAAAGTAAGACCGAAGGTAAACCAATCCTACCCACC-Y-3'
103	SOT-108-B7	5'-X-GGTGGGTGAGGCAGTTATCTAAGACCGAAGGTACCCCAATCCTACCCACC-Y-3'
104	SOT-108-C2	5'-X-GGTGGGTGAGGCAGTCTTGTAAGTCCGAAGGTAAACCAATCCTACCCACC-Y-3'
105	SOT-108-C3	5'-X-GGTGGGTGAGGCATAAAGTAAGACCGAAGGTAAACCAATCCTACCCGCC-Y-3'
106	SOT-108-A1	5'-X-GGTGGGTGAGGCATATGTCTAAGTCCGAAGGTAAACCAATCCTACCCACC-Y-3'
107	SOT-108-A3	5'-X-GGTGGGTGAGGCCTAAATAAGACCGAAGGTAAACCAATCCTACCCACC-Y-3'
108	SOT-108-A4	5'-X-GGTGGGTGAGGCACGCAATAAGACCGAAGGTAAACCAATCCTACCCACC-Y-3'
109	SOT-108-A5	5'-X-GGTGGGTGAGGCGGTTCAATTAAGTCCGAAGGTAAACCAATCCTACCCACC-Y-3'
110	SOT-108-B1	5'-X-GGTGGGTGAGGCAGTAATGTAAAGTCCGAAGGTAAACCAATCCTACCCACC-Y-3'
111	SOT-108-B3	5'-X-GGTGGGTGAGGCAATTAAGTAAAGTCCGAAGGTAAACCAATCCTACCCACC-Y-3'
112	SOT-108-B6	5'-X-GGTGGGTGAGGCATGCAAGTAAAGTCCGAAGGTAAACCAATCCTACCCACC-Y-3'
113	SOT-108-C4	5'-X-GGTGGGTGAGGCATTAAAGTAAAGTCCGAAGGTAAACCAATCCTACCCACC-Y-3'
114	SOT-108-C6	5'-X-GGTGGGTGAGGCACACAATAAGTCCGAAGGTAAACCAATCCTACCCACC-Y-3'
115	SOT-108-C8	5'-X-GGTGGGTGAGGCAGACACGTAAGTCCGAAGGTAAACCAATCCTACCCACC-Y-3'
116	SOT-108-D5	5'-X-GGTGGGTGAGGCACACCCATAAGTCCGAAGGTAAACCAATCCTACCCACC-Y-3'
117	SOT-108-E6	5'-X-GGTGGGTGAGGCGTACAAATAAGTCCGAAGGTAAACCAATCCTACCCACC-Y-3'
118	SOT-108-F1	5'-X-GGTGGGTGAGGCATAAAGTAAGACCGAAGGTAAACCAATCCTACCCACC-Y-3'
119	SOT-108-F2	5'-X-GGTGGGTGAGGCAGCTATGTAAAGTCCGAAGGTAAACCAATCCTACCCACC-Y-3'
120	SOT-108-F7	5'-X-GGTGGGTGAGGCAATCCGATAAGTCCGAAGGTAAACCAATCCTACCCACC-Y-3'
121	SOT-108-G3	5'-X-GGTGGGTGAGGCAGTAAAGTAAGACCGAAGGTAAACCAATCCTACCCACC-Y-3'
122	SOT-108-G7	5'-X-GGTGGGTGAGGCATAAAGTAAGTCCGAAGGTAAACCAATCCTACCCACC-Y-3'
123	SOT-108-H4	5'-X-GGTGGGTGAGGCAGTTCAAGTAAAGTCCGAAGGTAAACCAATCCTACCCACC-Y-3'
124	SOT-108-H5	5'-X-GGTGGGTGAGGCAGTAAATAAGTCCGAAGGTAAACCAATCCTACCCACC-Y-3'
125	SOT-108-D4	5'-X-GGTGGGTGAGGCAATCTGGTGAGGCAGATGTAAAGACCGAAGGTAAACCAATCCTACCCACC-Y-3'

Fig. 31

BEST AVAILABLE COPY

10/53

43/61

BEST AVAILABLE COPY




Figure 32A

10/522582

44/61




Figure 32B

BEST AVAILABLE COPY

10/522582

BEST AVAILABLE COPY




Figure 32C

000022502

46/61

Seq ID	name	Sequence	size (nt)	Original clone
87	Bot d lr 054	GGTGGGTGAGGCAGTAATGTAAGTCCGAAGGTAACCAATCCTACCCACC	49	SOT-108-B1
88	Bot d lr 055	GGGTGAGGCAGTAATGTAAGTCCGAAGGTAACCAATCCTACCC	43	SOT-108-B1
89	Bot d lr 056	GGGTGAGGCAGACACGTAAGACCGAAGGTAACCAATCCTACCC	43	SOT-108-C8
90	Bot d lr 057	GGTGGGTGAGGCAGCTATGTAAGTCCGAAGGTAACCAATCCTACCCACC	49	SOT-108-P2
91	Bot d lr 058	GGGTGAGGCAGCTATGTAAGTCCGAAGGTAACCAATCCTACCC	43	SOT-108-P2
92	Bot d lr 059	GGGTGAGGCATGCAAGTAAGTCCGAAGGTAACCAATCCTACCC	43	SOT-108-B6
93	Bot d lr 060	GGGTGAGGCAGTTATGTAAGACCGAAGGTAACCAATCCTACCC	43	SOT-108-B7
94	Bot d lr 061	GGTGGGTGAGGCACACCCATAAGTCCGAAGGTAACCAATCCTACCCACC	49	SOT-108-D5
95	Bot d lr 062	GGGTGAGGCACACCCATAAGTCCGAAGGTAACCAATCCTACCC	43	SOT-108-D5
96	Bot d lr 063	GGGTGAGGCAATCCGATAAGTCCGAAGGTAACCAATCCTACCC	43	SOT-108-P7
97	Bot d lr 064	GGGTGAGGCAGTAAGTAAGACCGAAGGTAACCAATCCTACCC	43	SOT-108-G3
98	Bot d lr 065	GGGTGAGGCAGTTCAGTAAGTCCGAAGGTAACCAATCCTACCC	43	SOT-108-H4
99	Bot d lr 066	GGGTGAGGCGTACAAATAAGTCCGAAGGTAACCAATCCTACCC	43	SOT-108-E6
100	Bot d lr 067	GGGTGAGGCACACAAATAAGTCCGAAGGTAACCAATCCTACCC	43	SOT-108-C6

Fig. 33

BEST AVAILABLE COPY

Inhibition of Ghrelin Activity by Spiegelmers Ranking of Reselection Clones




Figure 34

BEST AVAILABLE COPY

48/61

Inhibition of Ghrelin Activity by Spiegelmers Dose-Response Titration of Reselection clones




Figure 35

BEST AVAILABLE COPY

10/522582

49/61

FIRST EXPERIMENT




Fig. 36 A

BEST AVAILABLE COPY

122506

50/61




Fig. 36 B

BEST AVAILABLE COPY

51/61

SECOND EXPERIMENT




Fig. 37 A

BEST AVAILABLE COPY

10/522582

BEST AVAILABLE COPY

52/61




Fig. 37 B

16.02.62

53/61

TOTAL




Fig. 38 A

NOT AVAILABLE COPY

BEST AVAILABLE COPY

54/61






Fig. 38 B

10/322582

55/61
MEAL TRAINING
FIRST EXPERIMENT





MEAL TRAINING
FIRST EXPERIMENT



Figs. 39 A (top) and 39 B (bottom)

BEST AVAILABLE COPY

10/522012


56/61
MEAL TRAINING
SECOND EXPERIMENTMEAL TRAINING
SECOND EXPERIMENT

Figs. 40 A (top) and 40 B (bottom)


BEST AVAILABLE COPY

10/522582

57/61
MEAL TRAINING
TOTAL



MEAL TRAINING
TOTAL



Figs. 41 A (top) and 41 B (bottom)

REST AVAILABLE COPY

16/522582

BEST AVAILABLE COPY

^{58/61}
I.C.V EXPERIMENT (24 hours)
(Male Wistar Rats)




Fig. 42

10/522582

59/61

GH after Ghrelin stimulus (n=6)





Fig. 43

BEST AVAILABLE COPY

10/522582

60/61

Effects of acute administration of ghrelin on food intake in male Sprague-Dawley rats



Results are expressed as means + SEM for groups of 8 rats. Statistical comparisons were by one-way analysis of variance ($P > 0.05$ at 1, 2 and 4 h).

Fig. 44

BEST AVAILABLE COPY

61/61

